Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04986423 · ClinicalTrials.gov registry record · Phase 2

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Zenith Epigenetics.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT04986423: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Zenith Epigenetics.

NCT04986423 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Zenith Epigenetics. The registered enrollment target is 200 participants, roughly in line with the 195-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target. The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04986423, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Zenith Epigenetics.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: \< 6 months duration on abiraterone or failure to achieve PSA50 response while on abiraterone Cohort B: Patients with response to prior abiraterone, defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA \< 0.2 ng/mL, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and confirmed PSA50 response

Primary Outcome

Time from date of randomization to the date of first disease radiographic progression or death for any reason. Radiographic progression disease will be evaluated by RECIST 1.1 and PCWG3.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Enzalutamide
  • DRUG ZEN003694

Study Locations (20)

California

  • California Research Institute - Los Angeles
  • University of California, San Francisco - San Francisco
  • Innovative Clinical Research Institute - Whittier

Florida

  • D&H Cancer Research Center, LLC - Margate
  • BRCR Global - Plantation

Colorado

  • Colorado Urology - Lakewood

Louisiana

  • Hematology Oncology Clinic - Baton Rouge

Maryland

  • Maryland Oncology Hematology, P.A. - Columbia

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

New York

  • Weill Cornell Medical College - New York Presbyterian Hospital - New York

North Carolina

  • Messino Cancer Center - Asheville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-09-08
Est. Completion 2026-06
Phase Phase 2
Zenith Epigenetics

4 total trials

What NCT04986423 shows while recruiting

NCT04986423 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 195-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.

NCT04986423 names 20 study sites across 17 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT04986423 about?

NCT04986423 is a clinical study titled "ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer". This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. Th...

What is the current status of trial NCT04986423?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2021-09-08. Estimated completion is 2026-06.

What conditions does trial NCT04986423 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT04986423?

The interventions under investigation include: Enzalutamide (DRUG), ZEN003694 (DRUG).

Who is sponsoring clinical trial NCT04986423?

This trial is sponsored by Zenith Epigenetics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04986423 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04986423's enrollment target sits among peer trials

200 19th of 69 higher than 51 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04986423

Source: ClinicalTrials.gov NCT04986423, the US trial registry maintained by the National Library of Medicine. NCT04986423 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.